Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gadobutrol - Bayer HealthCare Pharmaceuticals

Drug Profile

Gadobutrol - Bayer HealthCare Pharmaceuticals

Alternative Names: BAY-864875; Gadavist; Gadobutrol injection for MRI of CNS - Bayer; Gadovist; Gadovist 1.0; Gd-DO3A-butriol; SHL 562

Latest Information Update: 16 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer Schering Pharma
  • Developer Bayer HealthCare Pharmaceuticals
  • Class Gadolinium-containing contrast agents; Organometallic compounds; Small molecules
  • Mechanism of Action Magnetic resonance imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Breast cancer; Coronary artery disease; Vascular disorders
  • Clinical Phase Unknown Brain cancer

Most Recent Events

  • 15 Jul 2019 Launched for Coronary artery disease (Diagnosis) in USA (IV)
  • 12 Jul 2019 Registered for Coronary artery disease (Diagnosis) in USA (IV)
  • 28 Dec 2018 Bayer completes a clinical trial in Vascular disorders (abdomen-lower extremity) (In volunteers, Diagnosis) in Japan (UMIN000025440)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top